Biodesix (BDSX) Cash from Financing Activities (2019 - 2026)

Biodesix has reported Cash from Financing Activities for 8 years, with the latest figure at $16.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 17319.59% year-over-year to $16.9 million; the trailing twelve-month figure through Mar 2026 stood at $33.2 million (down 35.32% YoY), and the FY2025 full-year result was $16.4 million, down 68.46% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $16.9 million, up from $1.7 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $51.3 million in Q2 2024, with the low at -$2.8 million in Q1 2022.
• Historically, Cash from Financing Activities has averaged $10.2 million across 5 years, with a median of $1.7 million in 2025.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 671.97% — and 2026, when it soared 17319.59%.
• Biodesix's Cash from Financing Activities stood at $41.8 million in 2022, then tumbled by 48.08% to $21.7 million in 2023, then plunged by 100.83% to -$181000.0 in 2024, then surged by 1044.2% to $1.7 million in 2025, then jumped by 888.71% to $16.9 million in 2026.
• The last three Cash from Financing Activities figures came in at $16.9 million (Q1 2026), $1.7 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.